Spyre Therapeutics presented at Citi's Biopharma Back to School Summit on September 9, 2026. Chief Executive Officer Cameron Turtle highlighted a cash balance of $1.1 billion at the end of the most recent quarter, giving the company runway into the second half of 2029. The firm’s market capitalization stands at $7.68 billion, though an InvestingPro analysis flagged the stock as potentially overvalued relative to its fair‑value estimate.
The company’s pipeline centers on three inflammatory bowel disease (IBD) mechanisms—alpha‑4 beta‑7 (code SPY001), IL‑23 (SPY003) and TL1A (SPY072)—and a long‑acting IL‑17 program (SPY007). Spyre is pursuing combination therapies across these targets in the SKYLINE Phase II trial, described as a Phase III‑sized study involving roughly 300 sites in more than 30 countries. Enrollment for the three combination arms began in April 2024 and is about five months into Part B. The trial will compare each combination against placebo and includes a contribution‑of‑components analysis. Readout is slated for 2027, with tighter timing guidance expected by late 2024 or early 2025.
Efficacy expectations are set at a 10‑percentage‑point improvement in clinical remission over standard of care, roughly an 8‑10% delta. In parallel, Spyre is testing TL1A plus bimekizumab against bimekizumab alone in a hidradenitis suppurativa (HS) study that targets the HiSCR75 endpoint rather than HiSCR50. The HS market is projected to reach about $10 billion at launch.
Seven TL1A proof‑of‑concept studies are ongoing across multiple indications. Spyre expects data from psoriatic arthritis and axial spondyloarthritis in Q4 2024, as well as Merck‑sponsored HS data and Roche‑sponsored atopic dermatitis and MASH data later in 2024. By 2025, the company anticipates up to four combination readouts—three in IBD and one in HS.
CEO Turtle emphasized the company’s funding position, stating, "We are very well‑funded for all the proof of concepts..." He also noted extensive use of artificial‑intelligence tools across functions, while clarifying that the antibodies themselves are not AI‑designed.
Spyre has financed its operations entirely through equity to date and expects future funding to involve partnership activity as its programs advance.
